- Esperion Therapeutics reported their Q1 earnings that revealed a beat on EPS and revenue.
- The company reported $13.4M in U.S. product revenue for Q1, which was up around 109% year-over-year.
- Esperion had a 32% year-over-year cost savings of the company operating expenses compared to the first quarter of 2021.
- The company believes they are "financed through the readout of the CLEAR Outcomes trial and for the foreseeable future beyond that".
- I believe investors should be applauding Esperion's recent success and ought to be enthusiastic about the company’s long-term potential.
For further details see:
Esperion Therapeutics: 2021 Labors Paying Off In 2022